Total Payments
$224,326
2024 Payments
$39,140
Companies
34
Transactions
357
Medicare Patients
95
Medicare Billing
$15,801
Payment Breakdown by Category
Consulting$153,717 (68.5%)
Other$51,726 (23.1%)
Food & Beverage$11,415 (5.1%)
Travel$7,468 (3.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $153,717 | 60 | 68.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,850 | 17 | 13.8% |
| Honoraria | $20,876 | 10 | 9.3% |
| Food and Beverage | $11,415 | 237 | 5.1% |
| Travel and Lodging | $7,468 | 33 | 3.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB, Inc. | $30,716 | 40 | $0 (2024) |
| GENZYME CORPORATION | $27,904 | 28 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $27,291 | 41 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $21,613 | 24 | $0 (2024) |
| Horizon Therapeutics plc | $17,554 | 18 | $0 (2023) |
| Amgen Inc. | $16,555 | 27 | $0 (2024) |
| PFIZER INC. | $15,269 | 20 | $0 (2024) |
| Janssen Biotech, Inc. | $11,662 | 30 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $11,433 | 12 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $10,224 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $39,140 | 44 | GENZYME CORPORATION ($18,060) |
| 2023 | $36,081 | 46 | UCB, Inc. ($10,973) |
| 2022 | $54,735 | 67 | Horizon Therapeutics plc ($13,667) |
| 2021 | $26,760 | 40 | Aurinia Pharma U.S., Inc. ($15,282) |
| 2020 | $15,262 | 12 | E.R. Squibb & Sons, L.L.C. ($6,000) |
| 2019 | $34,628 | 62 | E.R. Squibb & Sons, L.L.C. ($6,027) |
| 2018 | $4,425 | 38 | Janssen Biotech, Inc. ($2,083) |
| 2017 | $13,294 | 48 | E.R. Squibb & Sons, L.L.C. ($4,839) |
All Payment Transactions
357 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 12/10/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $45.72 | General |
| Category: Immunology | ||||||
| 11/22/2024 | SOBI, INC | — | Consulting Fee | Cash or cash equivalent | $2,997.00 | General |
| 11/18/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $88.88 | General |
| Category: Immunology | ||||||
| 11/15/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $149.09 | General |
| Category: Rheumatology | ||||||
| 11/15/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $138.60 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/15/2024 | Eli Lilly and Company | TALTZ (Drug) | Food and Beverage | In-kind items and services | $47.86 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/14/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $24.46 | General |
| Category: Rheumatology | ||||||
| 11/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 11/08/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $4,452.00 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $418.05 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $356.89 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $258.77 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | In-kind items and services | $175.88 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Food and Beverage | Cash or cash equivalent | $42.83 | General |
| 11/08/2024 | GENZYME CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $38.50 | General |
| 10/22/2024 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA | Food and Beverage | In-kind items and services | $142.44 | General |
| Category: Immunology | ||||||
| 10/16/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $125.01 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $50.25 | General |
| Category: IMMUNOLOGY | ||||||
| 09/16/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Immunology | ||||||
| 08/19/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: IMMUNOLOGY | ||||||
| 08/13/2024 | UCB, Inc. | Bimzelx (Biological) | Consulting Fee | Cash or cash equivalent | $2,840.00 | General |
| Category: Immunology | ||||||
| 07/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,240.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 28 | 36 | $7,020 | $3,412 |
| 2022 | 1 | 21 | 32 | $11,200 | $3,677 |
| 2021 | 1 | 15 | 39 | $13,650 | $4,277 |
| 2020 | 2 | 31 | 56 | $15,210 | $4,435 |
Total Patients
95
Total Services
163
Medicare Billing
$15,801
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 13 | 18 | $2,700 | $2,077 | 76.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 18 | $4,320 | $1,335 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 21 | 32 | $11,200 | $3,677 | 32.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 39 | $13,650 | $4,277 | 31.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 19 | 41 | $11,980 | $3,380 | 28.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 12 | 15 | $3,230 | $1,055 | 32.7% |
About Dr. Gail Kerr, MD
Dr. Gail Kerr, MD is a Internal Medicine healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1194725184.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gail Kerr, MD has received a total of $224,326 in payments from pharmaceutical and medical device companies, with $39,140 received in 2024. These payments were reported across 357 transactions from 34 companies. The most common payment nature is "Consulting Fee" ($153,717).
As a Medicare-enrolled provider, Kerr has provided services to 95 Medicare beneficiaries, totaling 163 services with total Medicare billing of $15,801. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Rheumatology
- Location Washington, DC
- Active Since 07/31/2005
- Last Updated 03/29/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1194725184
Products in Payments
- LUPKYNIS (Drug) $25,019
- XELJANZ (Drug) $15,158
- ORENCIA (Biological) $13,281
- SAPHNELO (Biological) $10,224
- Otezla (Drug) $10,133
- KRYSTEXXA (Biological) $8,132
- TREMFYA (Drug) $5,629
- KEVZARA (Drug) $5,434
- COSENTYX (Biological) $5,391
- KEVZARA (Biological) $4,884
- Hizentra (Biological) $4,793
- STELARA (Biological) $4,163
- Cimzia (Drug) $3,177
- SIMPONI ARIA (Biological) $3,122
- COSENTYX (Drug) $3,045
- Bimzelx (Biological) $2,983
- KRYSTEXXA (Drug) $1,784
- Humira (Biological) $465.11
- Enbrel (Biological) $302.77
- KEVZARA SARILUMAB INJECTION (Biological) $299.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Washington
Lawrence Dubuske, M.d, M.D
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Kavita Patel, M.d, M.D
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Andrea Singer
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Dr. Theo Hodge, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Ashte Collins, M.d, M.D
Internal Medicine — Payments: $837,513
Internal Medicine $837,513
Manish Shah, Md, MD
Internal Medicine — Payments: $456,731
Internal Medicine $456,731